Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 Enzymes in Environmental Toxicity and Cancer*

The mammalian CYP1A1, CYP1A2, and CYP1B1 genes (encoding cytochromes P450 1A1, 1A2, and 1B1, respectively) are regulated by the aromatic hydrocarbon receptor (AHR). The CYP1 enzymes are responsible for both metabolically activating and detoxifying numerous polycyclic aromatic hydrocarbons (PAHs) and aromatic amines present in combustion products. Many substrates for CYP1 enzymes are AHR ligands. Differences in AHR affinity between inbred mouse strains reflect variations in CYP1 inducibility and clearly have been shown to be associated with differences in risk of toxicity or cancer caused by PAHs and arylamines. Variability in the human AHR affinity exists, but differences in human risk of toxicity or cancer related to AHR activation remain unproven. Mouse lines having one or another of the Cyp1 genes disrupted have shown paradoxical effects; in the test tube or in cell culture these enzymes show metabolic activation of PAHs or arylamines, whereas in the intact animal these enzymes are sometimes more important in the role of detoxification than metabolic potentiation. Intact animal data contradict pharmaceutical company policies that routinely test drugs under development; if a candidate drug shows CYP1 inducibility, further testing is generally discontinued for fear of possible toxic or carcinogenic effects. In the future, use of “humanized” mouse lines, containing a human AHR or CYP1 allele in place of the orthologous mouse gene, is one likely approach to show that the AHR and the CYP1 enzymes in human behave similarly to that in mouse.

[1]  M. Denison,et al.  Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. , 2003, Annual review of pharmacology and toxicology.

[2]  K. Xue,et al.  Polymorphisms of the CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung carcinoma in Chinese population. , 2001, Mutation research.

[3]  D. Nebert,et al.  Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. , 2000, Biochemical and biophysical research communications.

[4]  D W Nebert,et al.  Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. , 1996, DNA and cell biology.

[5]  F. Gonzalez Role of Gene Knockout and Transgenic Mice in the Study of Xenobiotic Metabolism , 2003, Drug metabolism reviews.

[6]  R S McCuskey,et al.  Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Morris,et al.  Association of Ile462Val (Exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  F. Guengerich,et al.  Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. , 1996, Cancer research.

[9]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[10]  D. Nebert,et al.  Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse. Distinction between the "responsive" homozygote and heterozygote at the Ah locus. , 1975, Archives of Biochemistry and Biophysics.

[11]  D. Nebert,et al.  Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. , 1991, American journal of human genetics.

[12]  D. Nebert,et al.  Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture. I. Assay and properties of induced enzyme. , 1968, The Journal of biological chemistry.

[13]  D. Nebert,et al.  Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice. , 2002, Toxicology and applied pharmacology.

[14]  K. Noda,et al.  Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. , 1995, Carcinogenesis.

[15]  W. Tan,et al.  CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. , 2001, Carcinogenesis.

[16]  F. Gonzalez,et al.  Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. , 2001, Pharmacogenetics.

[17]  P. Grover,et al.  Enzyme-catalysed reactions of polycyclic hydrocarbons with deoxyribonucleic acid and protein in vitro. , 1968, The Biochemical journal.

[18]  D. Nebert,et al.  The in vivo and in vitro induction of aryl hydrocarbon hydroxylase in mammalian cells of different species, tissues, strains, and developmental and hormonal states. , 1969, Archives of biochemistry and biophysics.

[19]  M. Ingelman-Sundberg,et al.  In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. , 1997, Biochemical and biophysical research communications.

[20]  N P Wray,et al.  Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. , 1982, Cancer research.

[21]  D. Nebert,et al.  Mitochondrial reactive oxygen production is dependent on the aromatic hydrocarbon receptor. , 2002, Free radical biology & medicine.

[22]  Y. Fujii‐Kuriyama,et al.  Aryl hydrocarbon receptor mediates benzene-induced hematotoxicity. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  Mario Medvedovic,et al.  4-aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. , 2003, Journal of the National Cancer Institute.

[24]  J M Ward,et al.  Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. , 1996, Toxicology and applied pharmacology.

[25]  C. Jefcoate,et al.  Bone marrow cytotoxicity of benzo[a]pyrene is dependent on CYP1B1 but is diminished by Ah receptor-mediated induction of CYP1A1 in liver. , 2003, Toxicology and applied pharmacology.

[26]  T. Pineau,et al.  Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor , 1995, Science.

[27]  D W Nebert,et al.  The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. , 1989, Critical reviews in toxicology.

[28]  S. Orrenius,et al.  Cytochrome P-450 in human fetal liver microsomes. , 1971, Chemico-biological interactions.

[29]  T. Pineau,et al.  Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. , 1996, Pharmacogenetics.

[30]  J. Smart,et al.  Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. , 2000, Pharmacogenetics.

[31]  J. Ward,et al.  Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. E. Hahn,et al.  Aryl hydrocarbon receptors: diversity and evolution. , 2002, Chemico-biological interactions.

[33]  A. Luch,et al.  Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. , 2002, Chemical research in toxicology.

[34]  E. Snyderwine,et al.  Effect of CYP1A2 deficiency on heterocyclic amine DNA adduct levels in mice. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[35]  F. Curriero,et al.  Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. , 2004, Toxicology and applied pharmacology.

[36]  A. Conney Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the Seventh DeWitt S. Goodman Lecture. , 2003, Cancer research.

[37]  D. Nebert,et al.  Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. , 2000, Biochemical pharmacology.

[38]  J. Ward,et al.  CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. , 1999, Carcinogenesis.

[39]  C R Shaw,et al.  Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. , 1973, The New England journal of medicine.

[40]  E. Jabs,et al.  Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. , 1994, The Journal of biological chemistry.

[41]  T. Shimada,et al.  Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. , 2002, Carcinogenesis.

[42]  D. Rank,et al.  Sequence variation and phylogenetic history of the mouse Ahr gene. , 2002, Pharmacogenetics.

[43]  D W Nebert,et al.  Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Nebert,et al.  Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. , 2004, Molecular pharmacology.

[45]  T. Page,et al.  7,12-Dimethylbenz[a]anthracene-induced bone marrow toxicity is p53-dependent. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  K. Kawajiri,et al.  High Susceptibility to Lung Cancer Analyzed in Terms of Combined Genotypes of P450IA1 and Mu‐class Glutathione S‐Transferase Genes , 1992, Japanese journal of cancer research : Gann.

[47]  E. Glover,et al.  Tumour promotion by TCDD in skin of HRS/J hairless mice , 1982, Nature.

[48]  P. Harper,et al.  Polymorphisms in the human AH receptor. , 2002, Chemico-biological interactions.

[49]  J. Ward,et al.  Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. , 2003, Carcinogenesis.

[50]  O. Hankinson The aryl hydrocarbon receptor complex. , 1995, Annual review of pharmacology and toxicology.

[51]  L. Wattenberg,et al.  Benzpyrene hydroxylase activity in the gastrointestinal tract. , 1962, Cancer research.

[52]  C. Tohyama,et al.  Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  K. Tanaka,et al.  The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. , 1998, Pharmacogenetics.

[54]  F. Guengerich Metabolism of chemical carcinogens. , 2000, Carcinogenesis.

[55]  Y. Fujii‐Kuriyama,et al.  Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[56]  G. Kellermann,et al.  Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. , 1973, American journal of human genetics.